GlassScriptPhysician profile
Krishan K Gupta
NPI 1598769176
$25,678.02
in general payments reported to CMS, 2019-2025
26 companies · $816 in 2025
The $816 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,727 · 2020: $3,713 · 2021: $15K · 2022: $1,135 · 2023: $956 · 2024: $628 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $9,321.07 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $6,087.35 | 2019-2020 | |
| Abbvie INC. | $5,449.20 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $826.08 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $718.20 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $552.25 | 2019-2023 | Austedo, Austedo Xr |
| Tris Pharma INC | $480.09 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $399.37 | 2020-2024 | Trintellix |
| Alkermes, INC. | $350.91 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.09 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $194.73 | 2023-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $186.92 | 2019-2021 | |
| Lundbeck LLC | $168.47 | 2019-2024 | Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $140.21 | 2022-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $117.94 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $97.58 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $87.06 | 2019-2022 | |
| Indivior INC. | $54.21 | 2022-2025 | Sublocade, Perseris |
| Idorsia Pharmaceuticals US INC | $45.77 | 2022-2023 | Quviviq |
| Medicomp INC | $40.27 | 2025 | Telepatch Cardiac Monitor |
| E.R. Squibb & Sons, L.L.C. | $34.22 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $30.10 | 2023 | Spravato |
| Livanova USA, INC. | $23.76 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Merck Sharp & Dohme LLC | $13.90 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.76 | 2019 | |
| Neuronetics, INC. | $9.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishan Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.